Omega-3 (EPA/DHA): The Multi-System Baseline

We move beyond generic fish oil recommendations at Fishtown Medicine and treat omega-3 as a measurable, precision intervention. Standard guidelines treat ≥8% as "low risk," but I work with patients toward an Omega-3 Index of 12 to 15% for stronger heart resilience, brain protection, and an anti-inflammatory baseline consistent with the populations that have historically had the lowest cardiovascular and dementia event rates.

What omega-3 is and what it does

Omega-3 fatty acids are healthy fats your body cannot make on its own. The 2 that matter most for adults, EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), come mainly from oily fish like salmon, sardines, and anchovies, or from algae oil. They work by incorporating into cell membranes, lowering triglycerides, reducing inflammatory cytokines, and supporting the structural integrity and resolution signaling in the brain and heart. The Omega-3 Index is the blood test I care about most in this conversation. It measures EPA and DHA saturation in your red blood cell membranes, giving a reliable picture of your tissue levels over the past 120 days, not just what you ate yesterday. The ranges look like this:

• High-risk (under 4%): linked with higher statistical risk for sudden cardiac events and unchecked chronic inflammation.
• Intermediate (4 to 8%): where most new patients land. "Standard" in modern American eating, but it leaves significant room for improvement.
• Guideline-acknowledged "low risk" floor (8 to 12%): the conventional Harris/von Schacky target. A meaningful improvement over the American baseline and the threshold at which sudden cardiac death risk drops sharply.
• FTM target (12 to 15%): matches the tissue saturation seen in populations with high marine intake (e.g., Japanese coastal communities) that have historically had the lowest cardiovascular and dementia event rates. This is where we aim, dosed with a Rx-grade or third-party-tested formulation, with the AF caveat surfaced explicitly.
• Above 15%: historically seen in extreme marine-intake populations like the Inuit. We do not push patients here without a specific clinical reason.

Not all omega-3s do the same job. EPA is the primary driver for mood support and managing systemic inflammation. DHA is the structural scaffolding of the brain and retina, making it the priority for cognitive preservation, prenatal care, and recovery after concussions or traumatic brain injury (TBI). For inflammation-linked mood challenges, look for supplements with a 4:1 EPA to DHA ratio (or at least 60% EPA). For neuroprotection, aim for at least 600 to 1,000 mg of DHA per day.

Who this is for (and who it isnt)

Omega-3 fits a wide range of adults. It tends to fit:

• Most Philly adults who dont eat oily fish 3 or more times per week. Philadelphias classic comfort foods (cheesesteaks, hoagies, pretzels, pizza) deliver a lot of omega-6 fats and very little omega-3. An omega-3 supplement is often the simplest correction.
• Heart and metabolic health patients. High-dose omega-3 (2,000 to 4,000 mg per day) reliably lowers fasting triglycerides by 20 to 30%, often more than diet alone.
• Brain and mood support. Higher-EPA formulations (1,000 to 2,000 mg of EPA per day) have shown modest benefit for depression in randomized trials when added to standard treatment.
• Joint and autoimmune conditions. Higher omega-3 intake is linked with reduced joint pain in rheumatoid arthritis and modest improvement in psoriasis at 2,000 to 4,000 mg per day.
• APOE4 carriers. If you carry the APOE4 variant (linked to higher Alzheimers risk), we use higher doses (3,000 to 4,000 mg) and emphasize salmon roe or oily fish, which deliver omega-3 in the phospholipid form that may reach the brain more efficiently.

It needs a conversation first, or is not the right first move, if:

• You take a blood thinner (Eliquis, Xarelto, warfarin, daily aspirin) or have a bleeding disorder. Omega-3 modestly thins the blood, so dose and monitoring need to be coordinated.
• You have a history of atrial fibrillation. High doses (4 grams or more per day) have been linked with a small increase in AFib risk. Coordinate with your cardiologist.
• You have surgery scheduled in the next 7 to 14 days. Most surgeons ask patients to stop fish oil before elective surgery to reduce bleeding risk.

How we evaluate it: safety, then effectiveness, then cost

Every supplement we recommend runs the same 3 gates, in order (we go deep on this in how we choose supplements).

• Safety first. We look for third-party testing: IFOS (International Fish Oil Standards) certification or USP verification. High-quality, third-party-tested fish oils are filtered to undetectable levels of mercury, PCBs, and dioxins. Cheaper oils, especially store-brand ethyl esters, do not always meet that standard. A strong fishy smell means the oil is rancid and should be discarded.
• Effectiveness second. Most one-a-day multivitamins contain only 300 mg of fish oil, far too small a dose to move biomarkers. The number that matters on the label is the combined EPA plus DHA per serving, not the total fish oil number on the front. We also prefer the re-esterified triglyceride (rTG) form (such as Nordic Naturals) over the cheaper ethyl ester (EE) form, which is poorly absorbed and harder on the stomach.
• Cost last. A 90-day supply of a high-quality rTG or algae omega-3 usually costs $30 to $60. A direct-to-consumer Omega-3 Index test typically runs $50 to $100. Among clean, well-absorbed options, we take the best value.

How to dose it, and when

Here is what matters most: read the label for combined EPA plus DHA, because a "1,000 mg fish oil" softgel may carry only 300 mg of actual omega-3s.

• Foundational. I usually start patients at 2,000 mg of total EPA and DHA daily (typically 2 large softgels of rTG oil) to establish a baseline.
• Therapeutic. For high triglycerides or autoimmune conditions, we may titrate up to 4,000 mg daily under close supervision.
• APOE4 protocol. 3,000 to 4,000 mg daily, emphasizing phospholipid-form sources (salmon roe, oily fish).
• Take it with fat. Omega-3s are fat-soluble. Taking them on an empty stomach with black coffee drops absorption sharply. Take them with your largest meal of the day (avocado, olive oil, eggs, salmon all work).
• Consistency beats timing. These fats work by saturating your cell membranes over weeks. A missed dose is no crisis, but steady intake builds the reservoir.

What to expect on the timeline: triglyceride levels and joint stiffness can shift in 4 to 8 weeks. Raising your Omega-3 Index from a low value into the 12 to 15% target usually takes 3 to 4 months of consistent daily dosing, because red blood cells turn over slowly. We retest at month 3 to confirm you have reached target.

Cerebrovascular and stroke evidence

The omega-3 story for stroke is more nuanced than for sudden cardiac death, and the difference between observational biomarker data and RCT supplementation data is the key to understanding it.

• Observational, biomarker-based: A pooled analysis of 29 prospective cohorts (183,291 participants, 10,561 strokes) showed that the highest vs. lowest quintile of EPA was associated with a 17% lower total stroke risk (HR 0.83) and an 18% lower ischemic stroke risk (HR 0.82). DHA contributed similar but slightly smaller effects.
• RCT, supplementation-based: A Cochrane review of 31 trials found omega-3 supplementation made little or no difference to stroke risk (RR 1.02).
• The exception worth knowing: EPA monotherapy in REDUCE-IT (icosapent ethyl 4 g/day, prescription) reduced non-fatal stroke by 29% (RR 0.71) in patients with established cardiovascular disease or diabetes already on a statin. EPA+DHA combination products did not show the same effect.

The likely resolution: the trials that showed nothing used mixed EPA/DHA capsules at modest doses without measuring or targeting the Omega-3 Index. The trials and biomarker cohorts that showed a signal used higher EPA fractions and / or sustained high tissue saturation. This is exactly why we measure O3I instead of guessing. The 2024 AHA/ASA Primary Prevention of Stroke Guideline assigned a Class 3 (no benefit) recommendation for omega-3 supplementation for stroke risk reduction, based on the negative-trial body of evidence. The 2026 ACC/AHA Dyslipidemia Guideline carries a separate Class 2b recommendation for icosapent ethyl (4 g/day) in adults ≥50 with established ASCVD or diabetes plus another risk factor, persistent TG 150-499 mg/dL, and LDL < 100 on maximally tolerated statin. We respect both positions; our practice pattern below sits ahead of the formal criteria because we are treating to an Omega-3 Index biomarker target rather than waiting for the trial-defined entry conditions.

How we use omega-3 in clinic (and why we move earlier than the Class 2b criteria)

Our clinical position is that omega-3 does reduce MACE and stroke risk - when product quality, dose, and biomarker targeting are right. The negative-trial evidence is not, in our reading, an indictment of omega-3; it is an indictment of under-dosed, poorly-characterized OTC fish oil given without measuring tissue levels. Most of the null trials used ~1 g/day of mixed EPA+DHA - which is the same exposure profile the biomarker cohorts call "low risk." That is the protocol the null trials studied. It is not the protocol we use. The supporting case for our position:

• REDUCE-IT (icosapent ethyl 4 g/day, pharmaceutical-grade EPA) showed a 25% MACE reduction (NNT 21 over 4.9 years) and a 28% reduction in stroke as a secondary outcome. Quality + dose mattered.
• The biomarker data (Omega-3 Index, EPA, DHA tissue levels) consistently associates higher levels with lower MACE, stroke, and all-cause mortality across hundreds of thousands of participants. The Framingham Offspring analysis showed 39% lower incident CVD in the top O3I quintile.
• The 2024 stroke-prevention Class 3 position and the 2026 Class 2b dyslipidemia position both rest heavily on trials that used mixed EPA+DHA at 1 g/day or less without biomarker targeting, which is essentially the same exposure profile that the biomarker cohorts call "low risk".

What we actually prescribe:

• Lovaza (omega-3 acid ethyl esters, EPA+DHA Rx) when insurance covers it. It is FDA-approved for TG > 500 mg/dL, but we lean on it for ASCVD and cerebrovascular risk reduction in selected patients because the formulation is pharmaceutical-grade and well-characterized.
• Icosapent ethyl (Vascepa) at 4 g/day when the patient meets REDUCE-IT criteria (established ASCVD or diabetes + risk factor, on a statin, LDL 41-100, TG 150-499) and insurance covers it. This is the cleanest single-trial evidence path.
• Specific clean, third-party-tested EPA+DHA formulations at 2-3 g/day, dosed to lift the Omega-3 Index into the 12-15% target range. We do not use generic OTC fish oil because the dose, oxidation state, and EPA:DHA ratio are inconsistent and that exposure is what produced the null outcomes data.
• We start earlier than the formal Class 2b criteria in patients with elevated ApoB, residual ASCVD risk, family history of early MI or stroke, or a measured low O3I, regardless of TG level. We are treating to a biomarker target, not waiting for trial-defined entry criteria.
• The AF risk is real and worth surfacing. Both EPA-only and EPA+DHA increase AF risk in a dose-dependent way, particularly above ~1 g/day. In REDUCE-IT, hospitalization for AF was 3.1% on IPE vs. 2.1% on placebo (NNH ~91), and the risk was meaningfully higher in patients with prior AF (12.5% vs. 6.3%). In any patient with a history of palpitations, prior AF, or pacemaker, this is an explicit risk-benefit conversation - not a default add-on.

For the broader stroke and MACE primary-prevention picture, see the Stroke Prevention guide.

Flaws, side effects, and interactions

No supplement is perfect, and being honest about the downsides is part of the job.

• Fish burps and reflux. Usually means the oil is oxidized (rancid), in ethyl ester form, or was taken on an empty stomach. Switching to a rTG brand, freezing the capsules, and taking them with your largest meal usually fixes it. Enteric-coated softgels (which dissolve in the small intestine) are another option. If the bottle smells strongly fishy, throw it out.
• Mild blood thinning. Omega-3s have a mild anti-platelet effect. Highly saturated cell membranes are generally good for blood flow, but clotting time lengthens slightly. We advise a washout period of 7 to 14 days before scheduled surgery.
• Blood thinners. Combining omega-3 with prescription blood thinners (Eliquis, Xarelto, warfarin, daily aspirin) can raise bleeding risk. We often keep the dose modest (1 gram per day) and watch for unusual bruising.
• Atrial fibrillation. High-dose omega-3 (around 4 grams per day) has been linked with a small bump in atrial fibrillation risk. The data from REDUCE-IT and STRENGTH show the rhythm risk rises slightly while major cardiac events generally drop. For metabolically healthy patients, the cognitive and longevity benefits usually outweigh the AFib risk, but we coordinate with your cardiologist if this applies. If you feel a thumping or skipping in your chest, we adjust right away.
• LDL cholesterol. Some patients see a small rise in LDL when starting high-dose omega-3, particularly DHA-heavy products. We confirm with an ApoB test (a measurement of the actual number of harmful particles). If ApoB rises along with LDL, we adjust the formulation or dose.
• Statins. Omega-3 does not block statins. The combination has the strongest data for people with stubbornly high triglycerides or known plaque on imaging.

What we recommend, and what we dont

• We look for: the re-esterified triglyceride (rTG) form, IFOS or USP certified for purity and freshness, with a verified combined EPA plus DHA dose on the label. For plant-based patients or those with fish sensitivities, algae oil delivers bio-identical EPA and DHA without the fish.
• Worth considering: krill oil (phospholipid form, efficient absorption, useful if cost is less of a concern); prescription Vascepa (icosapent ethyl, 4 grams per day, purified EPA only with strong randomized trial data for reducing major cardiac events in high-risk patients with high triglycerides on a statin). We choose between them based on your risk profile, insurance, and lab values.
• We dont lean on: one-a-day multivitamin fish oil at 300 mg (too small to move biomarkers); ethyl ester bulk oils without third-party testing; ALA from flax or walnuts as a substitute (conversion to EPA and DHA is under 5% and usually falls short); doses above 4,000 mg per day without clear rationale and monitoring.

Guidance from the Clinic

"I often see patients taking fish oil for years, yet their Omega-3 Index is still sitting at 4%. Usually, it is a dosing or absorption issue. It is not enough to swallow the capsule. We need to verify that the EPA and DHA are getting into your cell membranes. Read for combined EPA plus DHA, pick the rTG form, take it with a real meal, and recheck your index at 3 months. That is most of the game." Dr. Ash

Key Takeaways

• Omega-3 (EPA and DHA) is a biomarker-driven intervention: we measure the Omega-3 Index and dose to a target of 8 to 12%, not a fixed pill count.
• Most adults need 2,000 mg of combined EPA plus DHA daily to establish a baseline; therapeutic targets (high triglycerides, autoimmune, APOE4) may require up to 4,000 mg.
• Choose the re-esterified triglyceride (rTG) form with IFOS or USP certification, and take it with a fatty meal.
• The main cautions are mild blood thinning (coordinate with blood thinners and plan a 7 to 14 day washout before surgery) and a small AFib risk at doses of 4 grams or more per day.
• Recheck the Omega-3 Index at 3 to 4 months and adjust dose to hit the 8 to 12% sweet spot.

If you'd like us to source it for you:

Scientific References

1. Harris, W. S., et al. (2017). The Omega-3 Index and relative risk for coronary heart disease mortality: Estimation from 10 cohort studies. Atherosclerosis, 262, 51-54.
2. Bhatt, D. L., et al. (2019). Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). New England Journal of Medicine, 380, 11-22.
3. Mozaffarian, D., & Wu, J. H. Y. (2011). Omega-3 Fatty Acids and Cardiovascular Disease: Effects on Risk Factors, Molecular Pathways, and Clinical Events. Journal of the American College of Cardiology, 58(20), 2047-2067.
4. Yokoyama, M., et al. (2007). Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS). Lancet, 369(9567), 1090-1098.